GSK PLC
Q3 2026 Form 13-F
LONDON
CIK 0001131399
· Publicly traded company
$497.0M Reported Value Total
Reported value
$497.0M
Quarter over quarter
-2.2%
Holdings
13
Top-10 concentration
98.1%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Victoria Whyte
Authorised Signatory for and on behalf of GSK plc
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 05, 2026 |
| Form | 13F-HR |
| Reported value | $497.0M |
| Positions | 13 |
| Change in reported value | -17.5% |
| New positions | 1 |
| Exited positions | 1 |
| Position turnover | 14.3% |
| Top-10 concentration | 98.1% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 5, 2026
|
13 | $497.0M |
|
Q2 2026 13F
Filed Aug 13, 2026
|
13 | $602.2M |
|
Q1 2026 13F
Filed May 14, 2026
|
13 | $599.2M |
|
Q4 2025 13F
Filed Feb 12, 2026
|
15 | $799.0M |
Top 13 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | CRSP CRISPR THERAPEUTICS AG | $144.3M | 29.03% |
| 2 | VIR VIR BIOTECHNOLOGY INC | $95.6M | 19.23% |
| 3 | WVE WAVE LIFE SCIENCES INC | $67.5M | 13.58% |
| 4 | BNTX BIONTECH SE | $65.7M | 13.22% |
| 5 | IDYA IDEAYA BIOSCIENCES INC | $51.2M | 10.31% |
| 6 | CYTK CYTOKINETICS INC | $22.4M | 4.51% |
| 7 | LYEL LYELL IMMUNOPHARMA INC | $14.8M | 2.98% |
| 8 | SPRO SPERO THERAPEUTICS INC | $11.1M | 2.24% |
| 9 | NKTX NKARTA INC | $8.3M | 1.66% |
| 10 | FULC FULCRUM THERAPEUTICS INC | $6.6M | 1.33% |
| 11 | BCYC BICYCLE THERAPEUTICS PLC | $5.6M | 1.13% |
| 12 | RGNX REGENXBIO INC | $2.0M | 0.41% |
| 13 | CVRX CVRX INC | $1.8M | 0.35% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.